


## PHARMACEUTICAL 2018

## Kura Oncology Inc. Rank 80 of 342





## PHARMACEUTICAL 2018



## Kura Oncology Inc. Rank 80 of 342

The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Kura Oncology Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 137% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	94,641
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,031
Liabilities, Non-Current	5,955
Other Assets	1,200
Other Compr. Net Income	-31
Other Expenses	36,077
Other Liabilities	0
Other Net Income	643
Other Revenues	0
Property and Equipment	10
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	95,851
Liabilities	15,986
Expenses	36,077
Revenues	0
Stockholders Equity	79,865
Net Income	-35,434
Comprehensive Net Income	-35,450
Economic Capital Ratio	182%

